23 October 2022 | News
Facility will enhance Aragen’s offerings in clinical formulation development and manufacturing
image credit- shutterstock
Aragen, a leading contract research development and manufacturing organization (CRDMO), has announced that it will operationalise its state-of-the-art formulation manufacturing facility in the Mallapur campus, Hyderabad, India by January 2023.
The 12,000 square feet new facility will strengthen the company’s ability to deliver clinical supplies to customers through its integrated drug substance and drug product development and manufacturing.
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting – with expansion plans already in place to add nano milling and hot melt extrusion capabilities.
These new capabilities at the Mallapur Campus will further enhance Aragen’s New Chemical Entity (NCE) early-stage development offerings, providing customers the convenience to discover and develop drugs from a co-located facility. It will provide greater flexibility to deliver customers’ clinical supply needs in multiple dosage forms, with process technologies and flexible batch sizes as low as 1000 units to as high as 100000 units.